News Biotech and big pharma heading for a M&A filled 2018 After a relatively quiet 12 months for mergers and acquisitions in 2017, this year is expected to produce a bumper crop of deals between big pharma and biotech.
News Johnson & Johnson back in 'exclusive' talks to buy Actelion Deal expected to be worth around $30 billion.
News BIND accepts Pfizer bid following bankruptcy Bid of $20 million may be enough to acquire all of BIND's assets.
Articles Celgene’s new CEO weighs in to drug pricing debate Celgene's new CEO Mark Alles discusses pricing and M&A, criticises Valeant's approach. Richard Staines reports.
News Neuralink gets okay for its first international trial Elon Musk's brain-computer interface (BCI) company Neuralink has been given the green light to test its device in tetraplegic patients in Canada
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
